Skip to main content
. 2023 Jan 1;19(1):156–166. doi: 10.7150/ijbs.76148

Figure 2.

Figure 2

The uptake of 5a-IRDye by subcutaneous BxPC-3 tumor depends on the 5a moiety. (A) Nude mice bearing-BxPC-3 tumors were injected i.v. with the indicated amount of Cys-IRDye, 5a-IRDye, or 5a-IRDye plus an excess of 5a, and imaged at the indicated time points using an IVIS imaging system, 30-35 days after tumor implantation. Pseudocolor images of representative mice for each group of treatment are shown (blue and green arrows indicate tumor and kidney, respectively). Quantification of the fluorescence uptake by BxPC-3 tumors and tumor-to-background ratio are shown in the lower panels (graphs, means ± SE of 3-4 mice/group; *, P<0.05 and **, P<0.01 by ordinary one-way ANOVA of the area under the curve for each tumor using GraphPad Prism software). (B) Similar experiment showing the tumor uptake of 5a-IRDye compared to 5a-Scr-IRDye. Blue and green arrows in pseudocolor images indicate tumor and kidney, respectively, while black arrow indicates the intestine. **, P<0.01; ***P<0.001 by ordinary one-way ANOVA. Black arrow indicates 5a-Scr-IRDye accumulation in the intestine (as confirmed by ex vivo analysis of the isolated organ, not shown).